TY - JOUR T1 - Guidance for laboratories performing molecular pathology for cancer patients JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 923 LP - 931 DO - 10.1136/jclinpath-2014-202404 VL - 67 IS - 11 AU - Ian A Cree AU - Zandra Deans AU - Marjolijn J L Ligtenberg AU - Nicola Normanno AU - Anders Edsjö AU - Etienne Rouleau AU - Francesc Solé AU - Erik Thunnissen AU - Wim Timens AU - Ed Schuuring AU - Elisabeth Dequeker AU - Samuel Murray AU - Manfred Dietel AU - Patricia Groenen AU - J Han Van Krieken Y1 - 2014/11/01 UR - http://jcp.bmj.com/content/67/11/923.abstract N2 - Molecular testing is becoming an important part of the diagnosis of any patient with cancer. The challenge to laboratories is to meet this need, using reliable methods and processes to ensure that patients receive a timely and accurate report on which their treatment will be based. The aim of this paper is to provide minimum requirements for the management of molecular pathology laboratories. This general guidance should be augmented by the specific guidance available for different tumour types and tests. Preanalytical considerations are important, and careful consideration of the way in which specimens are obtained and reach the laboratory is necessary. Sample receipt and handling follow standard operating procedures, but some alterations may be necessary if molecular testing is to be performed, for instance to control tissue fixation. DNA and RNA extraction can be standardised and should be checked for quality and quantity of output on a regular basis. The choice of analytical method(s) depends on clinical requirements, desired turnaround time, and expertise available. Internal quality control, regular internal audit of the whole testing process, laboratory accreditation, and continual participation in external quality assessment schemes are prerequisites for delivery of a reliable service. A molecular pathology report should accurately convey the information the clinician needs to treat the patient with sufficient information to allow for correct interpretation of the result. Molecular pathology is developing rapidly, and further detailed evidence-based recommendations are required for many of the topics covered here. ER -